Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 3213-3216

  Schmidt, B ^a   Korn, K ^a   Moschik, B ^a   Paatz, C ^a   Uberla, K ^a   Walter, H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS GENE; VIRUS MUTATION;

CARBAMATES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

EID: 0033743891     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.3213-3216.2000     Document Type: Article

References (25)

1. Amprenavir
2. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
3. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
4. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
5. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
6. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
7. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
8. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
9. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
10. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team
11. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
12. Changing patterns of mortality across Europe in patients infected with HIV-1
13. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
14. Unique resistance profile of the protease inhibitor amprenavir (141W94) observed in vitro and in the clinic
15. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
16. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
17. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
18. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
19. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice
20. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
21. Mutations in retroviral genes associated with drug resistance: 1999-2000 update
22. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
23. Antihuman immunodeficiency virus drug combination strategies
24. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
25. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment